Educational evidence summaries. No dosing, sourcing, or treatment instructions.
Sermorelin evidence, approval history and comparison articles.
Compare two GHRH receptor agonists by molecular design, duration, human evidence, historical approval and current regulatory status.
Reviewed by Regulatory Review DeskA regulatory history of sermorelin, including former Geref products, discontinuation and the status of compounded preparations.
Reviewed by CJC Axis Editorial TeamA mechanism-first comparison of sermorelin and ipamorelin, with clear boundaries between signaling, human evidence and clinical claims.
Reviewed by Clinical Trial Review TeamA map of GHRH analogues and ghrelin-receptor secretagogues showing where CJC-1295, sermorelin, ipamorelin and GHRP-6 fit.
Reviewed by Sports Integrity DeskAn athlete-focused overview of CJC-1295, ipamorelin, sermorelin and GHRP-6 under the 2026 anti-doping framework.
Reviewed by Clinical Trial Review TeamAn evidence-led Sermorelin review focused on evidence checklist, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review TeamAn evidence-led Sermorelin review focused on research gaps map, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led Sermorelin review focused on glucose and metabolic context, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review TeamAn evidence-led Sermorelin review focused on healthy-aging claims, human-study limits, regulatory context and claim verification.
Reviewed by Regulatory Review Desk